Low- and high-dose fluticasone propionate in asthma; effects during and after treatment

The dose dependency of the effects of inhaled corticosteroids on markers of asthmatic airway inflammation have not been well studied. There is a need to study the dose/response effects on this inflammation. In order to determine the dose/response effects of fluticasone propionate (FP), 24 asthmatic subjects were randomized to low- (100 microg x day(-1)) or high-dose (1,000 microg x day(-1)) FP for six weeks followed by placebo for 3 weeks. During treatment, the median increase in forced expiratory volume in one second (FEV1)was 12% in the high-dose group (p<0.05) and 10% in the low-dose group (p<0.05) (p>0.05 between groups); the median decrease in the percentage of sputum eosinophils was 93% in the high-dose group (p<0.05) and 46% in the low-dose group (p<0.05) (p>0.05 between groups). Symptoms, salbutamol use, morning peak flow, provocative concentration of methacholine causing a 20% fall in FEV1 (PC20), sputum eosinophil cationic protein concentration and tryptase activity improved significantly in both groups (p<0.05), but only the improvement in salbutamol use was greater in the high-dose group (p<0.05). During the run-out, the improvements in FEV1 and PC20 were rapidly reversed in both groups, but the improvements in peak flow and tryptase activity persisted; the improvement in sputum eosinophil concentration persisted only in the high-dose group (p<0.05). It was concluded that dose/response effects for FP are not easily demonstrable because low-dose FP is quite effective. For most outcomes, the effects of high- and low-dose FP are relatively short-lived after treatment is stopped. This finding raises questions about the extent to which inhaled corticosteroids are disease-modifying in asthma.

This article has been cited by other articles:

				M. Lommatzsch, K. Schloetcke, J. Klotz, K. Schuhbaeck, D. Zingler, C. Zingler, O. Schulte-Herbruggen, H. Gill, P. Schuff-Werner, and J. C. Virchow Brain-derived Neurotrophic Factor in Platelets and Airflow Limitation in Asthma Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 115 - 120. [Abstract] [Full Text] [PDF]

				A. Foresi, B. Mastropasqua, A. Chetta, R. D'Ippolito, R. Testi, D. Olivieri, and A. Pelucchi Step-Down Compared to Fixed-Dose Treatment With Inhaled Fluticasone Propionate in Asthma Chest, January 1, 2005; 127(1): 117 - 124. [Abstract] [Full Text] [PDF]

				D. C. Grootendorst and K. F. Rabe Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 77 - 87. [Abstract] [Full Text] [PDF]

				M Masoli, M Weatherall, S Holt, and R Beasley Clinical dose-response relationship of fluticasone propionate in adults with asthma Thorax, January 1, 2004; 59(1): 16 - 20. [Abstract] [Full Text] [PDF]

				A R A Sovijarvi, T Haahtela, H J Ekroos, A Lindqvist, A Saarinen, T Poussa, and L A Laitinen Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment Thorax, June 1, 2003; 58(6): 500 - 504. [Abstract] [Full Text] [PDF]

				G. Hawkins, A. D McMahon, S. Twaddle, S. F Wood, I. Ford, and N. C Thomson Stepping down inhaled corticosteroids in asthma: randomised controlled trial BMJ, May 22, 2003; 326(7399): 1115. [Abstract] [Full Text] [PDF]

				N C Thomson and M Shepherd Leukotriene receptor antagonists as add-on therapy for adults with asthma Thorax, March 1, 2003; 58(3): 190 - 192. [Abstract] [Full Text] [PDF]

				S. O'Sullivan, L. Cormican, M. Murphy, L. W. Poulter, and C. M. Burke Effects of Varying Doses of Fluticasone Propionate on the Physiology and Bronchial Wall Immunopathology in Mild-to-Moderate Asthma Chest, December 1, 2002; 122(6): 1966 - 1972. [Abstract] [Full Text] [PDF]

				N.J. Vanacker, E. Palmans, R.A. Pauwels, and J.C. Kips Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats Eur. Respir. J., October 1, 2002; 20(4): 873 - 879. [Abstract] [Full Text] [PDF]

				Leader of the Working Group:, J.C. Kips, Members of the Working Group:, M.D. Inman, L. Jayaram, E.H. Bel, K. Parameswaran, M.M.M. Pizzichini, I.D. Pavord, R. Djukanovic, et al. The use of induced sputum in clinical trials Eur. Respir. J., July 1, 2002; 20(37_suppl): 47S - 50s. [Full Text] [PDF]

				J. L. Faul, E. A. Demers, C. M. Burke, and L. W. Poulter Alterations in Airway Inflammation and Lung Function During Corticosteroid Therapy for Atopic Asthma* Chest, May 1, 2002; 121(5): 1414 - 1420. [Abstract] [Full Text] [PDF]

				G W Chalmers, K J Macleod, S A Little, L J Thomson, C P McSharry, and N C Thomson Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma Thorax, March 1, 2002; 57(3): 226 - 230. [Abstract] [Full Text] [PDF]

				M. J. VISSER, D. S. POSTMA, L. R. ARENDS, T. W. DE VRIES, E. J. DUIVERMAN, and P. L. P. BRAND One-Year Treatment with Different Dosing Schedules of Fluticasone Propionate in Childhood Asthma . Effects on Hyperresponsiveness, Lung Function, and Height Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2073 - 2077. [Abstract] [Full Text] [PDF]

				J C Kips and R A Pauwels Low dose inhaled corticosteroids and the prevention of death from asthma Thorax, September 1, 2001; 56(90002): ii74 - 78. [Full Text] [PDF]

				R. Beasley, P.J. Sterk, H.A.M. Kerstjens, and M. Decramer Comparative studies of inhaled corticosteroids in asthma Eur. Respir. J., April 1, 2001; 17(4): 579 - 580. [Full Text] [PDF]